Cargando…

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy

Background: Inflammatory cellular response is implicated in the pathogenesis of colorectal cancer (CRC). Nevertheless, the dynamic effects of inflammatory index coNLR (neutrophil-to-lymphocyte ratio)-PLR (platelet-to-lymphocyte ratio) during chemotherapy remain elusive. Methods: The baseline clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Yong, Yuan, Danping, Pang, Hongshuang, Wu, Hongbiao, Liu, Dongfang, Jin, Ningning, Wu, Ningning, Qiu, Jianming, Cao, Yuepeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497472/ https://www.ncbi.nlm.nih.gov/pubmed/31114335 http://dx.doi.org/10.2147/CMAR.S191712

Ejemplares similares

Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment
por: Zhou, Yeting, et al.
Publicado: (2023)

Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy
por: Lin, Gui-Nan, et al.
Publicado: (2016)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells
por: Tam, Shing-Yau, et al.
Publicado: (2023)

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
por: Okada, Shunji, et al.
Publicado: (2017)

Predictive impact of the inflammation‐based indices in colorectal cancer patients with adjuvant chemotherapy
por: Tao, Yong, et al.
Publicado: (2018)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
por: Funasaka, Chikako, et al.
Publicado: (2019)

FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis
por: Zhang, Yiyi, et al.
Publicado: (2020)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
por: Porcello Marrone, Luiz Carlos, et al.
Publicado: (2013)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Identification of the predictive genes for the response of colorectal cancer patients to FOLFOX therapy
por: Lin, Hengjun, et al.
Publicado: (2018)

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
por: Yang, I-Ping, et al.
Publicado: (2019)

Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy
por: Guo, Guifang, et al.
Publicado: (2019)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2020)

FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
por: Guan, Yue, et al.
Publicado: (2020)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
por: Soon, Wai Cheong, et al.
Publicado: (2014)

Received Signal Strength-Based Indoor Localization Using Hierarchical Classification
por: Zhang, Chenbin, et al.
Publicado: (2020)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
por: Qin, Shukui, et al.
Publicado: (2018)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer
por: Faure, Marjorie, et al.
Publicado: (2017)

Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF
por: Xie, Honghu, et al.
Publicado: (2019)

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019)

Urachal Adenocarcinoma: A Rare Primary Cancer Managed With FOLFOX Chemotherapy
por: Patel, Jay, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial
por: Howells, Lynne M, et al.
Publicado: (2019)

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
por: Han, Song-Hee, et al.
Publicado: (2019)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_o3bpcqt68ls54vt97fp709fr28